During clinical rounds, the infectious disease service evaluates a 68-year-old male admitted with a two-week history of nocturnal sweats, generalized malaise, and a newly detected holosystolic murmur at the cardiac apex. Transesophageal echocardiography reveals a 1.4-cm mobile vegetation on the mitral valve along with moderate mitral regurgitation. The laboratory notifies the team that all four sets of blood cultures drawn upon admission are growing Enterococcus faecalis. The isolate demonstrates susceptibility to ampicillin, vancomycin, and daptomycin, but exhibits high-level resistance to gentamicin. Renal function is within normal limits. Which of the following is the most appropriate intravenous antibiotic regimen for this patient?
- Ampicillin and ceftriaxoneCevap
- BAmpicillin and gentamicin
- CAmpicillin monotherapy
- DDaptomycin monotherapy
- ELinezolid monotherapy
Cevap
The most appropriate regimen is the combination of ampicillin and ceftriaxone.
Enterococcal infective endocarditis strictly requires bactericidal therapy to eradicate the infection from avascular heart valve vegetations. Because ampicillin alone is only bacteriostatic against Enterococcus faecalis, it must be combined with a synergistic agent. Traditionally, an aminoglycoside (e.g., gentamicin) is used. However, this isolate has high-level aminoglycoside resistance (HLAR), meaning the synergistic bactericidal effect of gentamicin is lost. The combination of ampicillin and ceftriaxone provides excellent synergistic bactericidal activity against E. faecalis by saturating complementary penicillin-binding proteins (PBPs). Ampicillin primarily binds PBPs 4 and 5, while ceftriaxone binds PBPs 2 and 3. This dual beta-lactam regimen is the standard of care for HLAR isolates and is increasingly preferred even for aminoglycoside-susceptible isolates due to its equivalent efficacy and lower risk of nephrotoxicity.
Adım Adım Çözüm
Anahtar Kavram
Treatment of Enterococcus faecalis infective endocarditis requires bactericidal synergy. In the presence of high-level aminoglycoside resistance (HLAR), dual beta-lactam therapy (ampicillin plus ceftriaxone) is the standard of care.